Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Show full item record



Permalink

http://hdl.handle.net/10138/234697

Citation

Kolstad , A , Pedersen , L B , Eskelund , C W , Husby , S , Gronbaek , K , Jerkeman , M , Laurell , A , Räty , R , Elonen , E , Andersen , N S , Brown , P D , Kimby , E , Bentzen , H , Sundstrom , C , Ehinger , M , Karjalainen-Lindsberg , M-L , Delabie , J , Ralfkiaer , E , Fagerli , U-M , Nilsson-Ehle , H , Lauritzsen , G F , Kuittinen , O , Niemann , C , Geisler , C H & Nordic Lymphoma Grp 2017 , ' Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years ' , Biology of Blood and Marrow Transplantation , vol. 23 , no. 3 , pp. 428-435 . https://doi.org/10.1016/j.bbmt.2016.12.634

Title: Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Author: Kolstad, Arne; Pedersen, Lone Bredo; Eskelund, Christian W.; Husby, Simon; Gronbaek, Kirsten; Jerkeman, Mats; Laurell, Anna; Räty, Riikka; Elonen, Erkki; Andersen, Niels Smedegaard; Brown, Peter deNully; Kimby, Eva; Bentzen, Hans; Sundstrom, Christer; Ehinger, Mats; Karjalainen-Lindsberg, Marja-Liisa; Delabie, Jan; Ralfkiaer, Elisabeth; Fagerli, Unn-Merete; Nilsson-Ehle, Herman; Lauritzsen, Grete Fossum; Kuittinen, Outi; Niemann, Carsten; Geisler, Christian Hartman; Nordic Lymphoma Grp
Other contributor: University of Helsinki, Hematologian yksikkö
University of Helsinki, Department of Medicine
University of Helsinki, Medicum







Date: 2017-03
Language: eng
Number of pages: 8
Belongs to series: Biology of Blood and Marrow Transplantation
ISSN: 1083-8791
DOI: https://doi.org/10.1016/j.bbmt.2016.12.634
URI: http://hdl.handle.net/10138/234697
Abstract: The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rear-rangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P
Subject: Mantle cell lymphoma
Autologous stem cell
transplantation
Minimal residual disease
Preemptive rituximab
MINIMAL RESIDUAL DISEASE
PROGRESSION-FREE SURVIVAL
TIME QUANTITATIVE PCR
RANDOMIZED-TRIALS
MULTIPLE-MYELOMA
PROGNOSTIC INDEX
IMMUNOCHEMOTHERAPY
REMISSION
NETWORK
PHASE-2
3121 General medicine, internal medicine and other clinical medicine
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1083879116312125_main.pdf 1.888Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record